ANI Pharmaceuticals (ANIP) Upgraded by TheStreet to “B”

ANI Pharmaceuticals (NASDAQ:ANIP) was upgraded by analysts at TheStreet from a “c+” rating to a “b” rating in a report issued on Tuesday.

A number of other research analysts have also commented on the company. Raymond James set a $73.00 price objective on ANI Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, February 28th. BidaskClub raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, February 14th. ValuEngine raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, February 4th. Finally, Cantor Fitzgerald set a $74.00 price target on ANI Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, December 28th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. ANI Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $71.50.

Shares of ANIP opened at $64.45 on Tuesday. The firm has a market capitalization of $750.29 million, a price-to-earnings ratio of 13.98 and a beta of 2.41. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.68 and a current ratio of 0.92. ANI Pharmaceuticals has a 52 week low of $36.92 and a 52 week high of $72.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Wednesday, February 27th. The specialty pharmaceutical company reported $1.32 EPS for the quarter, beating the Zacks’ consensus estimate of $1.24 by $0.08. The firm had revenue of $57.12 million for the quarter, compared to analyst estimates of $53.48 million. ANI Pharmaceuticals had a return on equity of 28.84% and a net margin of 7.69%. The business’s quarterly revenue was up 20.8% compared to the same quarter last year. During the same period last year, the company earned $1.08 EPS. Analysts forecast that ANI Pharmaceuticals will post 5.74 EPS for the current year.

In other news, insider Arthur Przybyl sold 27,625 shares of the stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $63.53, for a total value of $1,755,016.25. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Robert W. Schrepfer sold 4,651 shares of the firm’s stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $64.43, for a total value of $299,663.93. Following the sale, the senior vice president now directly owns 53,484 shares in the company, valued at approximately $3,445,974.12. The disclosure for this sale can be found here. Corporate insiders own 33.10% of the company’s stock.

A number of institutional investors have recently modified their holdings of ANIP. First Trust Advisors LP acquired a new stake in ANI Pharmaceuticals during the 3rd quarter worth $710,000. Bessemer Group Inc. acquired a new stake in ANI Pharmaceuticals during the 3rd quarter worth $138,000. Teachers Retirement System of The State of Kentucky raised its stake in ANI Pharmaceuticals by 99.5% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 2,005 shares of the specialty pharmaceutical company’s stock worth $113,000 after buying an additional 1,000 shares during the period. Thomson Horstmann & Bryant Inc. raised its stake in ANI Pharmaceuticals by 5.3% during the 3rd quarter. Thomson Horstmann & Bryant Inc. now owns 25,156 shares of the specialty pharmaceutical company’s stock worth $1,422,000 after buying an additional 1,258 shares during the period. Finally, Panagora Asset Management Inc. acquired a new stake in ANI Pharmaceuticals during the 3rd quarter worth $1,052,000. 59.75% of the stock is currently owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.

See Also: How does a 12b-1 fee affect fund performance?

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.